BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• Press Releases

  Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 6, 2024

  December 9, 2024

   · 

  3 min read
• Press Releases

  Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

  December 9, 2024

   · 

  4 min read
• Press Releases

  Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 6, 2024

  December 9, 2024

   · 

  1 min read
• Press Releases

  BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

  December 9, 2024

   · 

  6 min read
• Press Releases

  Charles R. Scheper, Chairman of Bexion Pharmaceuticals Board, Named Great Living Cincinnatian

  December 9, 2024

   · 

  4 min read
• Press Releases

  Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 6, 2024

  December 9, 2024

   · 

  1 min read
• Press Releases

  Zevra Therapeutics Announces Organizational Changes

  December 9, 2024

   · 

  4 min read
• Press Releases

  Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

  December 9, 2024

   · 

  6 min read
• Press Releases

  Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND

  December 9, 2024

   · 

  5 min read
• Press Releases

  Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

  December 9, 2024

   · 

  4 min read